SEC Tracker
Get the app

Actuate Therapeutics ACTU

Actuate Therapeutics (ACTU) filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational progress. The filing highlights Actuate's continued advancement of its pipeline of novel cancer therapies, a critical focus area for the company as it seeks to drive long-term shareholder value. Investors will look to this report for insights into Actuate's near-term growth prospects and ability to execute on its strategic initiatives.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Actuate Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lite Strategy LITS public float $43M, Dec 31, 2025
  2. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025
  3. Fortress Biotech FBIO public float $44M, Jun 30, 2025
  4. CervoMed CRVO public float $40M, Jun 30, 2025
  5. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025